Should I Buy NTLA? NTLA 2026 Analysis

Should You Buy Intellia Therapeutics Inc (NTLA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

12.280

1 Day change

10.73%

52 Week Range

28.250

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price action is in a sharp downtrend today (-9% regular session) with bearish momentum (MACD worsening) and no proprietary buy signals.
While the stock looks oversold and near support (possible short-term bounce setup), insiders are aggressively selling, which is a poor near-term backdrop.
Options positioning is bullish-leaning (calls dominant), but that alone isn’t enough to override the negative trend/momentum.
Near-term catalyst risk: earnings on 2026-02-25 (after hours) can swing the stock materially; without a clear edge, the risk/reward is unattractive today.

Technical Analysis

Trend/momentum: Bearish. MACD histogram is negative (-0.311) and expanding lower, indicating downside momentum is strengthening.
Oscillators: RSI(6) ~25.3 suggests the stock is oversold (bounce risk rises), but oversold can stay oversold in biotech selloffs.
Moving averages: Converging MAs suggests potential basing, but no confirmed reversal signal is indicated.
Key levels: Price 11.255 is below S1 (11.709) and approaching S2 (10.339). If S2 breaks, downside can accelerate; any rebound likely faces overhead supply near the pivot ~13.926.
Pattern-based forecast provided: low expected drift (next month slightly negative), not supportive of a high-conviction immediate entry.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment/skew: Put/call ratios are very low (OI 0.31; volume 0.15), implying call-heavy positioning and relatively bullish/“risk-on” sentiment.
Activity: Today’s option volume is elevated vs the 30-day average (~27.5x), signaling heightened attention/speculation.
Volatility: 30D IV ~90.4 vs historical vol ~77.7; IV percentile ~60.6 suggests options are priced rich (market expecting large moves, consistent with biotech + upcoming earnings).

Technical Summary

Sell

Buy

Positive Catalysts

- Regulatory/program sentiment improved recently: FDA lifted the clinical hold for Nex-z hATTR-PN trial (noted in analyst updates), which can restore some confidence in the platform/program.
- Analyst narrative (recent): multiple firms highlighted valuation disconnect and path back into clinic as supportive.
- Upcoming catalyst: QDEC 2025 earnings on 2026-02-25 (after hours) could reset expectations if commentary/data is constructive.

Neutral/Negative Catalysts

- Strong near-term bearish tape: large single-day drawdown (-9% regular market) with worsening MACD momentum.
- Insider activity: insiders are selling; selling amount increased ~2235.78% over the last month (clear negative signal).
- No supportive news flow in the past week to explain/offset the selloff.
- Clinical/program overhang: prior safety concerns (patient death / liver toxicity context referenced in past downgrades) can keep valuation capped and make the stock fragile on any new adverse updates.
- Event risk: earnings soon; for an impatient entry, the timing risk is unfavorable.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $13.78M, up ~51.27% YoY (growth positive).
Profitability: Net income -$101.3M (loss widened vs prior year, down -25.34% YoY) and EPS -0.92 (down -31.34% YoY), indicating burn remains heavy.
Gross margin: 100% (typical for collaboration/other revenue mix; does not imply operating profitability).
Overall: Top-line improved, but losses widened—financial trend does not yet support a momentum-style “buy now” without a clear technical reversal.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: after a wave of downgrades/target cuts in Nov 2025 tied to safety/hold concerns, sentiment improved in late Jan 2026 following news that the FDA lifted the hold for Nex-z hATTR-PN.
Latest changes: Baird raised PT to $7 (Neutral), H.C. Wainwright raised PT to $25 (Buy), Citizens reiterated Outperform with $21 PT; earlier BofA kept Neutral with $12 PT.
Wall Street pros: hold lifted is a tangible de-risking step; some see a valuation disconnect and meaningful upside if programs progress.
Wall Street cons: credibility/safety overhang and prior severe adverse event kept multiple firms cautious; several prior downgrades suggest investors may remain intolerant of renewed setbacks.
Influential/political trading: No recent congress trading data available in the last 90 days.

22 Analyst Rating

Wall Street analysts forecast NTLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTLA is 16.5 USD with a low forecast of 4 USD and a high forecast of 54 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

12 Hold

1 Sell

Moderate Buy

Current: 11.090

Low

Averages

16.5

High

Current: 11.090

Low

Averages

16.5

High

Baird

Neutral

maintain

$4 -> $7

AI Analysis

2026-01-28

Reason

Baird

Price Target

$4 -> $7

AI Analysis

2026-01-28

maintain

Neutral

Reason

Baird raised the firm's price target on Intellia Therapeutics to $7 from $4 and keeps a Neutral rating on the shares. The firm updated its model following the lit of the FDA clinical hold for Nex-z hATTR-PN trial.

H.C. Wainwright

Mitchell Kapoor

Buy

maintain

$15 -> $25

2026-01-28

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$15 -> $25

2026-01-28

maintain

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Intellia Therapeutics to $25 from $15 and keeps a Buy rating on the shares. The FDA signaled that Nex-Z's clinical risk is manageable by lifting the clinical hold, but the market is still pricing in "an existential threat," the analyst tells investors in a research note. The firm upped its probability of approval to 35% from 25%.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NTLA

Unlock Now

NTLA Should I Buy

NTLA Should I Buy

Should You Buy Intellia Therapeutics Inc (NTLA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch